483
Novartis Pharmaceuticals CorporationNovartis Pharmaceuticals Corporation – FDA 483, Aug 5, 2014
Record Details
An FDA inspection of Novartis Pharmaceuticals Corp. in East Hanover, NJ, identified significant issues related to clinical trial oversight. The firm failed to promptly submit an IND safety report to the FDA and did not inform participating investigators in a timely manner regarding a suspected adverse reaction. Additionally, the inspection revealed a failure to ensure proper monitoring of the study, including missing monitoring visit reports and infrequent monitoring visits.
View Company Profile
ID · 7b7960f8-08c8-49f2-a0bc-275ee2905eaa
Other documents for Novartis Pharmaceuticals Corporation
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.